TOKYO, June 13 (Reuters) - Amgen Inc., the world's biggest biotechnology company, said on Tuesday it will triple the number of its employees in Japan by 2010 with the aim of building up a sales network to start selling new cancer drugs on its own. California-based Amgen has licensed out its medicines in Japan, the world's second-largest pharmaceutical market, to local firms, but its own sales staff will be marketing its drugs from around 2009, said Katsuaki Kato, director of business development and licensing of Amgen Ltd., the Japanese arm.
